Literature DB >> 24148617

Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors.

Daniela C Kroy1, Donatella Ciuffreda1, Jennifer H Cooperrider1, Michelle Tomlinson2, Garrett D Hauck1, Jasneet Aneja1, Christoph Berger3, David Wolski1, Mary Carrington4, E John Wherry5, Raymond T Chung1, Kenneth K Tanabe6, Nahel Elias7, Gordon J Freeman8, Rosemarie H de Kruyff9, Joseph Misdraji10, Arthur Y Kim11, Georg M Lauer12.   

Abstract

BACKGROUND & AIMS: There is an unclear relationship between inhibitory receptor expression on T cells and their ability to control viral infections. Studies of human immune cells have been mostly limited to T cells from blood, which is often not the site of infection. We investigated the relationship between T-cell location, expression of inhibitory receptors, maturation, and viral control using blood and liver T cells from patients with hepatitis C virus (HCV) and other viral infections.
METHODS: We analyzed 36 liver samples from HCV antibody-positive patients (30 from patients with chronic HCV infection, 5 from patients with sustained virological responses to treatment, and 1 from a patient with spontaneous clearance) with 19 paired blood samples and 51 liver samples from HCV-negative patients with 17 paired blood samples. Intrahepatic and circulating lymphocytes were extracted; T-cell markers and inhibitory receptors were quantified for total and virus-specific T cells by flow cytometry.
RESULTS: Levels of the markers PD-1 and 2B4 (but not CD160, TIM-3, or LAG-3) were increased on intrahepatic T cells from healthy and diseased liver tissues compared with T cells from blood. HCV-specific intrahepatic CD8(+) T cells from patients with chronic HCV infection were distinct in that they expressed TIM-3 along with PD-1 and 2B4. In comparison, HCV-specific CD8(+) T cells from patients with sustained virological responses and T cells that recognized cytomegalovirus lacked TIM-3 but expressed higher levels of LAG-3; these cells also had different memory phenotypes and proliferative capacity.
CONCLUSIONS: T cells from liver express different inhibitory receptors than T cells from blood, independent of liver disease. HCV-specific and cytomegalovirus-specific CD8(+) T cells can be differentiated based on their expression of inhibitory receptors; these correlate with their memory phenotype and levels of proliferation and viral control.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CMV; Costimulation; HCV; IHL; Immune Regulation; Inflammation; PBMC; T-Cell Exhaustion; cytomegalovirus; hepatitis C virus; intrahepatic lymphocyte; peripheral blood mononuclear cell

Mesh:

Substances:

Year:  2013        PMID: 24148617      PMCID: PMC3946973          DOI: 10.1053/j.gastro.2013.10.022

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  24 in total

Review 1.  Hepatitis C virus infection.

Authors:  G M Lauer; B D Walker
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

2.  High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection.

Authors:  Alleluiah Rutebemberwa; Stuart C Ray; Jacquie Astemborski; Jordana Levine; Lin Liu; Kimberly A Dowd; Shalyn Clute; Changyu Wang; Alan Korman; Alessandro Sette; John Sidney; Drew M Pardoll; Andrea L Cox
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

3.  Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy.

Authors:  Georg M Lauer; Michaela Lucas; Joerg Timm; Kei Ouchi; Arthur Y Kim; Cheryl L Day; Julian Schulze Zur Wiesch; Glaucia Paranhos-Baccala; Isabelle Sheridan; Deborah R Casson; Markus Reiser; Rajesh T Gandhi; Bin Li; Todd M Allen; Raymond T Chung; Paul Klenerman; Bruce D Walker
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression.

Authors:  Henry Radziewicz; Chris C Ibegbu; Marina L Fernandez; Kimberly A Workowski; Kamil Obideen; Mohammad Wehbi; Holly L Hanson; James P Steinberg; David Masopust; E John Wherry; John D Altman; Barry T Rouse; Gordon J Freeman; Rafi Ahmed; Arash Grakoui
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

5.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.

Authors:  Cheryl L Day; Daniel E Kaufmann; Photini Kiepiela; Julia A Brown; Eshia S Moodley; Sharon Reddy; Elizabeth W Mackey; Joseph D Miller; Alasdair J Leslie; Chantal DePierres; Zenele Mncube; Jaikumar Duraiswamy; Baogong Zhu; Quentin Eichbaum; Marcus Altfeld; E John Wherry; Hoosen M Coovadia; Philip J R Goulder; Paul Klenerman; Rafi Ahmed; Gordon J Freeman; Bruce D Walker
Journal:  Nature       Date:  2006-08-20       Impact factor: 49.962

6.  PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion.

Authors:  Simona Urbani; Barbara Amadei; Daniela Tola; Marco Massari; Simona Schivazappa; Gabriele Missale; Carlo Ferrari
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

7.  High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome.

Authors:  Victoria Kasprowicz; Julian Schulze Zur Wiesch; Thomas Kuntzen; Brian E Nolan; Steven Longworth; Andrew Berical; Jenna Blum; Cory McMahon; Laura L Reyor; Nahel Elias; William W Kwok; Barbara G McGovern; Gordon Freeman; Raymond T Chung; Paul Klenerman; Lia Lewis-Ximenez; Bruce D Walker; Todd M Allen; Arthur Y Kim; Georg M Lauer
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

8.  Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction.

Authors:  Lucy Golden-Mason; Brent Palmer; Jared Klarquist; John A Mengshol; Nicole Castelblanco; Hugo R Rosen
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

9.  LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.

Authors:  Joseph F Grosso; Cristin C Kelleher; Timothy J Harris; Charles H Maris; Edward L Hipkiss; Angelo De Marzo; Robert Anders; George Netto; Derese Getnet; Tullia C Bruno; Monica V Goldberg; Drew M Pardoll; Charles G Drake
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

10.  Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection.

Authors:  Michael A Paley; Daniela C Kroy; Pamela M Odorizzi; Jonathan B Johnnidis; Douglas V Dolfi; Burton E Barnett; Elizabeth K Bikoff; Elizabeth J Robertson; Georg M Lauer; Steven L Reiner; E John Wherry
Journal:  Science       Date:  2012-11-30       Impact factor: 47.728

View more
  43 in total

1.  PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection.

Authors:  Wen Xiao; Long Feng Jiang; Xiao Zhao Deng; Dan Yan Zhu; Jia Ping Pei; Mao Lei Xu; Bing Jun Li; Chang Jun Wang; Jing Hai Zhang; Qi Zhang; Zhen Xian Zhou; Wei Liang Ding; Xiao Dong Xu; Ming Yue
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

Review 2.  T-bet-expressing B cells during HIV and HCV infections.

Authors:  James J Knox; David E Kaplan; Michael R Betts
Journal:  Cell Immunol       Date:  2017-07-11       Impact factor: 4.868

Review 3.  Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy.

Authors:  Mohamed L Salem; Ahmed El-Badawy
Journal:  World J Hepatol       Date:  2015-10-18

Review 4.  T cell responses in hepatitis C virus infection: historical overview and goals for future research.

Authors:  Lauren Holz; Barbara Rehermann
Journal:  Antiviral Res       Date:  2014-11-26       Impact factor: 5.970

Review 5.  Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.

Authors:  Tai Hato; Andrew X Zhu; Dan G Duda
Journal:  Immunotherapy       Date:  2016-02-11       Impact factor: 4.196

Review 6.  Immune responses to HCV and other hepatitis viruses.

Authors:  Su-Hyung Park; Barbara Rehermann
Journal:  Immunity       Date:  2014-01-16       Impact factor: 31.745

7.  Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection.

Authors:  Jeffrey E Teigler; Gennadiy Zelinskyy; Michael A Eller; Diane L Bolton; Mary Marovich; Alexander D Gordon; Aljawharah Alrubayyi; Galit Alter; Merlin L Robb; Jeffrey N Martin; Steven G Deeks; Nelson L Michael; Ulf Dittmer; Hendrik Streeck
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

Review 8.  Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.

Authors:  John Attanasio; E John Wherry
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 9.  Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.

Authors:  Elia Moreno-Cubero; Juan-Ramón Larrubia
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

Review 10.  Innate and Adaptive Immune Responses in Chronic HCV Infection.

Authors:  Lynn B Dustin
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.